[ { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#provenance", "@graph": [ { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#assertion", "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ] } ] }, { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#Head", "@graph": [ { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#pubinfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] }, { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#assertion", "@graph": [ { "@id": "http://purl.obolibrary.org/obo/DOID_1787", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#association", "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [ { "@id": "http://purl.obolibrary.org/obo/DOID_1787" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [ { "@id": "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [ { "@id": "https://identifiers.org/drugbank:DB00682" } ], "@type": [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "\"Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [ see Warnings and Precautions (5.7) Use in Specific Populations (8.1 see Use in Specific Populations (8.1) Warfarin sodium is contraindicated in patients with: Hemorrhagic tendencies or blood dyscrasias Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces [ see Warnings and Precautions (5.8) Bleeding tendencies associated with: - Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract - Central nervous system hemorrhage - Cerebral aneurysms, dissecting aorta - Pericarditis and pericardial effusions - Bacterial endocarditis Threatened abortion, eclampsia, and preeclampsia Unsupervised patients with conditions associated with potential high level of non-compliance Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) [ see Adverse Reactions (6) Major regional or lumbar block anesthesia Malignant hypertension Pregnancy, except in women with mechanical heart valves. ( 4 5.7 8.1 Hemorrhagic tendencies or blood dyscrasias. ( 4 Recent or contemplated surgery of the central nervous system (CNS) or eye, or traumatic surgery resulting in large open surfaces. ( 4, 5.8) Bleeding tendencies associated with certain conditions. ( 4 Threatened abortion, eclampsia, and preeclampsia. ( 4 Unsupervised patients with potential high levels of non-compliance. ( 4 Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding. ( 4 Hypersensitivity to warfarin or any component of the product. ( 4 Major regional or lumbar block anesthesia. ( 4 Malignant hypertension. ( 4\"" } ], "https://w3id.org/biolink/vocab/provided_by": [ { "@id": "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation": [ { "@id": "https://schema.org/MedicalContraindication" } ] }, { "@id": "https://identifiers.org/drugbank:DB00682", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Drug" } ] } ] }, { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#pubinfo", "@graph": [ { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "I0GtQu+4sOFGNijxYLWQg6PkNm7ooan+fMz8OYNVMBKvG6dS1118Akz4DREhsNBctReFIkKBB7LVIqVycJzapJ/7xCOpLzf8x6dfhRunmcrhu30HpsYWQ7y55IejGjkZtmMTS/oGg/7nC63rAViSQHdJXzOE8sJ/93UYdFrXDLg=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU" } ] }, { "@id": "http://purl.org/np/RAshatPzeZvix6B6XKefZ5midNGuGW88Zu6mQ-zmnZJuU", "http://purl.org/dc/terms/created": [ { "@value": "2021-08-23T12:41:53.913+02:00", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://purl.org/dc/terms/creator": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [ { "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [ { "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] } ] } ]